THERAPY DOSSIER · th-6a1c75b6bc0b

AP39 (mitochondria-targeted slow-releasing hydrogen sulfide donor)

Drug · AP39, a mitochondria-targeted slow-release hydrogen-sulfide donor (tool compound).

Evidence & regulatory context

Mechanism: AP39, a mitochondria-targeted slow-release hydrogen-sulfide donor (tool compound).
Target: Not recorded
Injury models: Haemorrhage/shock
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29927788 ↗2019Mixed findings

The Mitochondria-Targeted H2S-Donor AP39 in a Murine Model of Combined Hemorrhagic Shock and Blunt Chest Trauma.

MouseHaemorrhage/shockControlledC57BL/6MaleIntravenous bolus100 nmol/kg (high dose) or 10 nmol/kg (low dose)At start of resuscitation, after 1 h of haemorrhage

Model: Blast wave-induced blunt chest trauma (TxT) followed by 1 h haemorrhagic shock and 4 h resuscitation

High dose AP39 attenuated systemic inflammation and reduced pulmonary iNOS and IkappaB alpha expression, but in the combined trauma plus haemorrhagic shock group it produced the lowest mean arterial pressure, highest norepinephrine requirement and higher mortality. Low dose AP39 had no haemodynamic…

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…